Research programme: CAK-1 inhibitors - Roche
Latest Information Update: 21 Jun 2000
At a glance
- Originator Roche
- Mechanism of Action Phosphotransferase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 21 Jun 2000 Discontinued-Preclinical for Mycoses in Japan (Unknown route)
- 01 Feb 2000 New profile
- 01 Feb 2000 Preclinical development for Mycoses in Japan (Unknown route)